BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 21381966)

  • 1. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia: clinical impact of antimicrobial resistance on outcome.
    Joo EJ; Kang CI; Ha YE; Kang SJ; Park SY; Chung DR; Peck KR; Lee NY; Song JH
    Microb Drug Resist; 2011 Jun; 17(2):305-12. PubMed ID: 21381966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa.
    Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
    Microb Drug Resist; 2005; 11(1):68-74. PubMed ID: 15770098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems.
    Lee CH; Su TY; Ye JJ; Hsu PC; Kuo AJ; Chia JH; Lee MH
    J Microbiol Immunol Infect; 2017 Oct; 50(5):677-683. PubMed ID: 26188977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imipenem resistance among pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes.
    Lautenbach E; Weiner MG; Nachamkin I; Bilker WB; Sheridan A; Fishman NO
    Infect Control Hosp Epidemiol; 2006 Sep; 27(9):893-900. PubMed ID: 16941312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pseudomonas aeruginosa bacteremia: associations with a source of infection and antibiotic resistance].
    Dambrauskiene A; Adukauskiene D; Jeroch J; Vitkauskiene A
    Medicina (Kaunas); 2009; 45(1):1-7. PubMed ID: 19223699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial Effects of β-Lactams on Imipenem-Resistant Ceftazidime-Susceptible Pseudomonas aeruginosa.
    Wi YM; Choi JY; Lee JY; Kang CI; Chung DR; Peck KR; Song JH; Ko KS
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antimicrobial susceptibility of Pseudomonas aeruginosa isolated at Kochi Municipal Central Hospital in the last 3 years].
    Nasu Y; Abe M; Ono N; Araki M; Horimi T; Takahashi I
    Jpn J Antibiot; 2004 Oct; 57(5):438-48. PubMed ID: 15655905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States.
    Sader HS; Huband MD; Castanheira M; Flamm RK
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069652
    [No Abstract]   [Full Text] [Related]  

  • 9. Risk factors for recovery of imipenem- or ceftazidime-resistant pseudomonas aeruginosa among patients admitted to a teaching hospital in Brazil.
    Fortaleza CM; Freire MP; Filho Dde C; de Carvalho Ramos M
    Infect Control Hosp Epidemiol; 2006 Sep; 27(9):901-6. PubMed ID: 16941313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imipenem resistance in Pseudomonas aeruginosa: emergence, epidemiology, and impact on clinical and economic outcomes.
    Lautenbach E; Synnestvedt M; Weiner MG; Bilker WB; Vo L; Schein J; Kim M
    Infect Control Hosp Epidemiol; 2010 Jan; 31(1):47-53. PubMed ID: 19951202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imipenem-resistant Pseudomonas aeruginosa: risk factors for nosocomial infections.
    Onguru P; Erbay A; Bodur H; Baran G; Akinci E; Balaban N; Cevik MA
    J Korean Med Sci; 2008 Dec; 23(6):982-7. PubMed ID: 19119440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Previous ciprofloxacin exposure is associated with resistance to beta-lactam antibiotics in subsequent Pseudomonas aeruginosa bacteremic isolates.
    López-Dupla M; Martínez JA; Vidal F; Almela M; Soriano A; Marco F; López J; Olona M; Mensa J
    Am J Infect Control; 2009 Nov; 37(9):753-8. PubMed ID: 19487049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evolution of antimicrobial resistance against Pseudomonas aeruginosa in a French university hospital between 2002 and 2006].
    Minchella A; Molinari L; Alonso S; Bouziges N; Sotto A; Lavigne JP
    Pathol Biol (Paris); 2010 Feb; 58(1):1-6. PubMed ID: 19875241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of resistance, cross-resistance and antimicrobial combinations for Pseudomonas aeruginosa isolates from 1997 to 2009.
    Master RN; Clark RB; Karlowsky JA; Ramirez J; Bordon JM
    Int J Antimicrob Agents; 2011 Oct; 38(4):291-5. PubMed ID: 21737249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of inappropriate empiric antimicrobial therapy on outcome in Pseudomonas aeruginosa bacteraemia: a stratified analysis according to sites of infection.
    Joo EJ; Kang CI; Ha YE; Park SY; Kang SJ; Wi YM; Lee NY; Chung DR; Peck KR; Song JH
    Infection; 2011 Aug; 39(4):309-18. PubMed ID: 21594653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic inflammatory response syndrome in adult patients with nosocomial bloodstream infection due to Pseudomonas aeruginosa.
    Marra AR; Bar K; Bearman GM; Wenzel RP; Edmond MB
    J Infect; 2006 Jul; 53(1):30-5. PubMed ID: 16253333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bacteremia due to Pseudomonas aeruginosa: results from a 3-year national study in the Slovak Republic.
    Koprnova J; Beno P; Korcova J; Mrazova M; Grey E; Liskova A; Harnicarova A; Karvaj M; Koval S; Zak V; Danaj M; Streharova A; Mitterpachova E; Miklosko J; Ondrusova A; Riedl J; Kaiserova E; Prokopova V; Hornova M; Payer J; Rudinsky B; Pevalova L; Bencelova M; Hanzen J; Macekova L; Csölleyova J; Krcmery V
    J Chemother; 2005 Oct; 17(5):470-6. PubMed ID: 16323434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluoroquinolone-resistant Pseudomonas aeruginosa: assessment of risk factors and clinical impact.
    Gasink LB; Fishman NO; Weiner MG; Nachamkin I; Bilker WB; Lautenbach E
    Am J Med; 2006 Jun; 119(6):526.e19-25. PubMed ID: 16750968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pseudomonas aeruginosa Infection after Pancreatoduodenectomy: Risk Factors and Clinic Impacts.
    Zhang JF; Zhu HY; Sun YW; Liu W; Huo YM; Liu DJ; Li J; Hua R
    Surg Infect (Larchmt); 2015 Dec; 16(6):769-74. PubMed ID: 26237502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint.
    Tam VH; Gamez EA; Weston JS; Gerard LN; Larocco MT; Caeiro JP; Gentry LO; Garey KW
    Clin Infect Dis; 2008 Mar; 46(6):862-7. PubMed ID: 18279040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.